Search hospitals > Illinois > Kewanee
Illinois CancerCare-Kewanee Clinic
Claim this profileKewanee, Illinois 61443
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
376 reported clinical trials
2 medical researchers
Summary
Illinois CancerCare-Kewanee Clinic is a medical facility located in Kewanee, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Kewanee Clinic is involved with conducting 376 clinical trials across 475 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Bryan A. FallerCrossroads Cancer Center2 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
226 reported clinical trials
291 drugs studied
James L. WadeDecatur Memorial Hospital3 years of reported clinical research
Studies Recurrence
Studies Breast Cancer
11 reported clinical trials
20 drugs studied
Clinical Trials running at Illinois CancerCare-Kewanee Clinic
Breast Cancer
Prostate Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Gastric Cancer
Esophageal Cancer
Squamous Cell Carcinoma
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Illinois CancerCare-Kewanee Clinic?
Illinois CancerCare-Kewanee Clinic is a medical facility located in Kewanee, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Kewanee Clinic is involved with conducting 376 clinical trials across 475 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Where is Illinois CancerCare-Kewanee Clinic located?
**Illinois CancerCare-Kewanee Clinic**
- **Address:** 1051 W South St, Kewanee, IL 61443
- **Location:** Approximately 1 mile west of downtown Kewanee, near the intersection of West South Street and Tenney Street.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Illinois CancerCare-Kewanee Clinic, please call (309) 243-3500 or toll-free at (866) 662-6564.
What insurance does Illinois CancerCare-Kewanee Clinic accept?
The Illinois CancerCare-Kewanee Clinic accepts most prescription insurance plans, including Medicare and Medicaid, and offers delivery options for prescriptions. They have a dedicated team focused on making medication affordable for patients. The clinic is affiliated with OSF Saint Luke's Medical Center, which accepts a variety of commercial and government health insurance plans. Patients should verify their insurance coverage and bring their insurance identification cards on their first visit.
What awards or recognition has Illinois CancerCare-Kewanee Clinic received?
Illinois CancerCare-Kewanee Clinic, situated in Kewanee, Illinois, specializes in treating cancer and blood diseases as part of the larger Illinois CancerCare practice. It is distinguished by its dedication to clinical research, maintaining around 100 open clinical cancer research trials at any given time. The clinic has earned recognition from the Quality Oncology Practice Initiative (QOPI®) Certification Program for meeting the highest national standards for quality cancer care and is a proud member of Heartland NCORP, leading the nation in cancer research enrollment.